City of Hope Launches Phase 2 Trial to Mitigate Heart Risks from Prostate Cancer Hormone Therapy
Event summary
- City of Hope has opened a phase 2 clinical trial (NCT07202247) to compare three strategies for protecting heart health in prostate cancer patients receiving androgen deprivation therapy (ADT).
- The trial will evaluate intermittent fasting, anti-obesity medication targeting GLP-1 signaling, and the American Heart Association’s Life’s Essential 8 guidelines over six months.
- The study aims to enroll 60 participants and will follow them for 12 months post-intervention to assess metabolic and cardiovascular health outcomes.
The big picture
City of Hope’s trial addresses a critical gap in managing the cardiometabolic side effects of ADT, a common treatment for prostate cancer. The study reflects a growing trend in oncology to integrate holistic health strategies into cancer care, potentially setting a new standard for supportive therapies. The outcomes could have broader implications for other hormone therapies with similar side effect profiles.
What we're watching
- Trial Outcomes
- Whether any of the three interventions will demonstrate superior efficacy in mitigating cardiometabolic risks associated with ADT.
- Patient Adherence
- The extent to which patients can sustain the prescribed interventions over the six-month trial period.
- Regulatory Impact
- How the trial results could influence future guidelines for managing cardiometabolic health in prostate cancer patients.
Related topics